• 2:44:03 - 2:47:09
Pfizer Whistleblower Confirms Bioweapon Global Extermination Plan Exposed – FULL SHOW 8/4/21
Pfizer IND Filings, Placebo Groups and Infection Rates
Analysis of Pfizer's Investigational New Drug (IND) filings reveals that the 95% efficacy claim was based on a very small number of infections within a six-month window. Karen Kingston explains that the trial assumed a 1.6% infection rate, meaning the vaccine only reduced the absolute risk of infection by approximately 1%. She characterizes the data as a statistical manipulation designed to favor authorization.